Perrigo CEO Resigns Immediately Due to Personal Conduct; Interim CEO Appointed
PRGO sits 25% above its 52-week low of $9.225.
Summary
Perrigo's CEO, Patrick Lockwood-Taylor, has resigned immediately due to personal conduct inconsistent with the company's code of conduct, prompting the appointment of board member Albert A. Manzone as interim CEO. The company reaffirmed its full-year 2026 financial outlook.
Key Events · Executive and Board Changes · PRGO
-
CEO Resignation
Patrick Lockwood-Taylor resigned as President and Chief Executive Officer and as a member of the Board of Directors, effective June 7, 2026.
-
Reason for Departure
The resignation was due to personal conduct inconsistent with the company's Code of Conduct and core values, explicitly stated as unrelated to business, strategy, operations, or financial reporting.
-
Interim CEO Appointed
Albert A. Manzone, a current director and Audit Committee member, has been appointed Interim President and Chief Executive Officer. A comprehensive search for a permanent successor has been initiated.
-
Financial Outlook Reaffirmed
Perrigo reaffirmed its full-year 2026 financial outlook, including All In net sales growth of (5.5)% to (1.5)% and All In adjusted EPS of $2.00 to $2.30, as previously provided on May 6, 2026.
Analysis · PRGO · Life Sciences
The unexpected resignation of a CEO, particularly due to personal conduct issues, introduces significant leadership uncertainty and potential reputational risk for the company. While the filing explicitly states the conduct was unrelated to the company's business or financials, such a departure can still impact investor confidence. The immediate appointment of an interim CEO from the board and the reaffirmation of the full-year financial outlook are crucial steps to mitigate the negative impact and signal continuity in operations and strategy, especially following a challenging first quarter with a substantial net loss. The market will now watch for updates on the permanent CEO search and any further details on the interim CEO's compensation.
At the time of this filing, PRGO was trading at $11.51 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $9.23 to $28.44. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.